New drug duo aims to shrink breast tumors before surgery
NCT ID NCT01723774
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests whether adding a targeted drug (PD 0332991) to standard hormone therapy (anastrozole) before surgery can better stop breast cancer cell growth in women with early-stage ER+ HER2- breast cancer. About 84 participants will receive the combination for several weeks before their operation. The goal is to see if this approach leads to more complete tumor responses compared to hormone therapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Mayo Clinic - Scottsdale
Scottsdale, Arizona, 85259, United States
-
University of Alabama
Birmingham, Alabama, 35233, United States
-
Washington University School of Medicine
St Louis, Missouri, 63122, United States
Conditions
Explore the condition pages connected to this study.